Document is current
Any future updates will be listed below
-
Authors
Smalley Rumfield, Claire
Pellom, Samuel T
Morillon II, Y Maurice
Schlom, Jeffrey https://orcid.org/0000-0001-7932-4072
Jochems, Caroline https://orcid.org/0000-0002-9000-9855
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02994953 at ClinicalTrials.govnct03721978 at ClinicalTrials.govDocuments that mention this clinical trial
Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours
https://doi.org/10.1136/gutjnl-2023-329650
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
https://doi.org/10.1136/jitc-2022-005813
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Generation and <i>in vivo</i> validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
https://doi.org/10.1136/jitc-2022-005282
265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort
https://doi.org/10.1136/jitc-2020-sitc2020.0265
nct02065973 at ClinicalTrials.govDocuments that mention this clinical trial
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
nct03669718 at ClinicalTrials.govDocuments that mention this clinical trial
Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy
https://doi.org/10.1136/jitc-2024-011074
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
nct03258008 at ClinicalTrials.govDocuments that mention this clinical trial
ISA101 and nivolumab for HPV-16<sup>+</sup> cancer: updated clinical efficacy and immune correlates of response
https://doi.org/10.1136/jitc-2021-004232
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).
https://doi.org/10.1200/jco.2024.42.16_suppl.6003
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer
https://doi.org/10.1136/jitc-2025-012555
nct02517398 at ClinicalTrials.govDocuments that mention this clinical trial
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
nct03427411 at ClinicalTrials.govDocuments that mention this clinical trial
116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
https://doi.org/10.1007/s11523-021-00809-2
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
480 Investigating genetic predisposition to immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-sitc2024.0480
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
https://doi.org/10.1007/s12325-019-01018-0
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-008480
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006
nct02994953 at ClinicalTrials.govDocuments that mention this clinical trial
116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies
https://doi.org/10.1136/ijgc-2021-esgo.8
44 Early kinetics of circulating tumor HPV-16 and HPV-18 DNA are associated with survival in patients with HPV-associated cancers treated with dual blockade of PD-L1 and TGF-β
https://doi.org/10.1136/jitc-2025-sitc2025.0044
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
https://doi.org/10.1136/ijgc-2019-esgo.100
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
https://doi.org/10.1136/jitc-2020-001395
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
https://doi.org/10.1136/jitc-2021-003113
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2022-004601
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
https://doi.org/10.1136/jitc-2022-005128
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
https://doi.org/10.1136/jitc-2020-000664
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2020-sitc2020.0375
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa
https://doi.org/10.1136/jitc-2021-sitc2021.006
Documents that mention this clinical trial
Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours
https://doi.org/10.1136/gutjnl-2023-329650
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
https://doi.org/10.1136/jitc-2022-005813
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
https://doi.org/10.1136/jitc-2020-000612
Generation and <i>in vivo</i> validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
https://doi.org/10.1136/jitc-2022-005282
265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort
https://doi.org/10.1136/jitc-2020-sitc2020.0265
-
Funding
Funding for this research was provided by:
PDS Technology (CRADA #03279)
Intramural Research Program, Center for Cancer Research, National Cancer Institute (ZIA BC 010944)
EMD Serono (CRADA #02666)
- License Information
